Weber on Oncology

 
 
  • Ipi Plus Nivo for Melanoma Patients With Brain Metastases   Two recent ASCO abstracts show important results, possibly practice-changing, on immunologic treatment in melanoma patients with brain metastases.
  • Adjuvant Nivolumab: New Standard of Care for Melanoma?   In resected melanoma, nivolumab improves recurrence-free survival with less toxicity. Dr Jeffrey Weber discusses results of the CheckMate 238 study presented at ESMO 2017
  • Top Melanoma Studies to Be Presented at ASCO   Dr Jeffrey Weber previews five melanoma treatment studies that he considers the ones to watch; one, he predicts, will be practice-changing.
  • Biomarkers to Determine Who Gets Checkpoint Inhibitors   Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.
  • Rare Melanomas Prove 'Hard to Get' Using Immunotherapy   Dr Jeffrey Weber assesses the benefit of immunotherapies in two rare subtypes of melanoma and finds that rates of survival and duration of response trail well behind those associated with cutaneous melanoma.
  • The Puzzling Prognostic Effect of LDH in Melanoma   Although LDH is a negative prognostic factor in melanoma, patients who receive checkpoint inhibitors may still have responses of long duration even when their LDH level is high.
  • Two Ipilimumab Trials Show Survival Benefit, and More Toxicity   Dr Weber discusses two studies that show a clear survival advantage with ipilimumab, but at a significant price in toxicity.
  • Stopping Immunotherapy Doesn't Stop Benefit   Two recent studies, as discussed by Dr Jeffrey Weber, indicate that melanoma patients who stop immunotherapy because of toxicity can do very well clinically over the long term.
  • Is Immunotherapy Safe for Older Melanoma Patients?   How do adverse events from immunotherapy compare in younger vs older patients? Dr Weber comments on the safety of checkpoint inhibitors for our older patients.
  • Will PD-1 Agents Edge Out Interferon in Adjuvant Melanoma?   Dr Jeffrey Weber reviews the current options for adjuvant therapy in patients with resected melanoma and looks ahead to the use of PD-1 antibodies in this setting.
  • The 'C' Word Whispered in Metastatic Melanoma   Is cure a possibility for some patients with metastatic melanoma? Dr Jeffrey Weber discusses long-term survival from the KEYNOTE-001 and COMBI-d studies, which show 'very impressive data indeed.'
  • Which Cancer Patient Is a Candidate for Immunotherapy?   Because immunotherapies are approved for multiple cancers, Drs Weber and Postow discuss choosing the right patient for immunotherapy, taking into account comorbidities and potential adverse events.
  • Findings From NEMO, and Other Melanoma Highlights   In a preview of ASCO melanoma studies, the NEMO results suggest that binimetinib is reasonable for NRAS-mutated melanoma, and combo regimens continue to show strong outcomes, reports Dr Jeffrey Weber.